These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20626746)

  • 21. X-linked adrenoleukodystrophy.
    Moser HW; Mahmood A; Raymond GV
    Nat Clin Pract Neurol; 2007 Mar; 3(3):140-51. PubMed ID: 17342190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
    Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
    Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
    Singh J; Olle B; Suhail H; Felicella MM; Giri S
    J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).
    Rasmussen M; Moser AB; Borel J; Khangoora S; Moser HW
    Neurochem Res; 1994 Aug; 19(8):1073-82. PubMed ID: 7800117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABC subfamily D proteins and very long chain fatty acid metabolism as novel targets in adrenoleukodystrophy.
    Morita M; Shimozawa N; Kashiwayama Y; Suzuki Y; Imanaka T
    Curr Drug Targets; 2011 May; 12(5):694-706. PubMed ID: 21039332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in X-linked adrenoleukodystrophy.
    Moser H; Dubey P; Fatemi A
    Curr Opin Neurol; 2004 Jun; 17(3):263-9. PubMed ID: 15167059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [X-linked adrenoleukodystrophy].
    Aubourg P
    Ann Endocrinol (Paris); 2007 Dec; 68(6):403-11. PubMed ID: 17532287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
    McGuinness MC; Zhang HP; Smith KD
    Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome.
    Moser HW
    J Inherit Metab Dis; 1995; 18(4):435-47. PubMed ID: 7494402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy.
    Asheuer M; Bieche I; Laurendeau I; Moser A; Hainque B; Vidaud M; Aubourg P
    Hum Mol Genet; 2005 May; 14(10):1293-303. PubMed ID: 15800013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diet therapy in the treatment of neuropediatric disorders].
    Chaves-Carballo E
    Rev Neurol; 2003 Aug 1-15; 37(3):267-74. PubMed ID: 12938059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy.
    Schlüter A; Espinosa L; Fourcade S; Galino J; López E; Ilieva E; Morató L; Asheuer M; Cook T; McLaren A; Reid J; Kelly F; Bates S; Aubourg P; Galea E; Pujol A
    Hum Mol Genet; 2012 Mar; 21(5):1062-77. PubMed ID: 22095690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil.
    Basu C; Ahmed MA; Kartha RV; Brundage RC; Raymond GV; Cloyd JC; Carlin BP
    J Biopharm Stat; 2016; 26(6):1025-1039. PubMed ID: 27547896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adrenoleukodystrophy: new approaches to a neurodegenerative disease.
    Moser HW; Raymond GV; Dubey P
    JAMA; 2005 Dec; 294(24):3131-4. PubMed ID: 16380594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of retinoids for induction of the redundant gene ABCD2 as an alternative treatment option in X-linked adrenoleukodystrophy.
    Weber FD; Weinhofer I; Einwich A; Forss-Petter S; Muneer Z; Maier H; Weber WH; Berger J
    PLoS One; 2014; 9(7):e103742. PubMed ID: 25079382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mixture of oleic, erucic and conjugated linoleic acids modulates cerebrospinal fluid inflammatory markers and improve somatosensorial evoked potential in X-linked adrenoleukodystrophy female carriers.
    Cappa M; Bizzarri C; Petroni A; Carta G; Cordeddu L; Valeriani M; Vollono C; De Pasquale L; Blasevich M; Banni S
    J Inherit Metab Dis; 2012 Sep; 35(5):899-907. PubMed ID: 22189598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy.
    Fourcade S; López-Erauskin J; Galino J; Duval C; Naudi A; Jove M; Kemp S; Villarroya F; Ferrer I; Pamplona R; Portero-Otin M; Pujol A
    Hum Mol Genet; 2008 Jun; 17(12):1762-73. PubMed ID: 18344354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
    Singh J; Khan M; Singh I
    Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid--a case report.
    Terre'Blanche G; van der Walt MM; Bergh JJ; Mienie LJ
    Lipids Health Dis; 2011 Aug; 10():152. PubMed ID: 21871076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lorenzo's oil: a reassessment.
    Poulos A; Robertson EF
    Med J Aust; 1994 Mar; 160(6):315-7. PubMed ID: 8133809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.